Rezultaty

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model

Dokumenty pełnotekstowe

Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs

Dokumenty pełnotekstowe

Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation

Dokumenty pełnotekstowe